In Brief:
SWITCH-1 was a phase 2b study assessing the efficacy, safety, and dose-response relationship of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of vasomotor symptoms. Elinzanetant resulted in significant and clinically meaningful improvements in vasomotor symptoms, sleep and quality of life and was well tolerated across all doses.
Go to Full Text of this Article